Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Druce KL, Gibson DS, McEleney K, Yimer BB, Meleck S, James B, Hellman B, Dixon WG, McBeth J. Remote sampling of biomarkers of inflammation with linked patient generated health data in patients with rheumatic and musculoskeletal diseases: an ecological momentary assessment feasibility study. BMC Musculoskelet Disord. 2022 Aug 13;23(1):770. doi: 10.1186/s12891-022-05723-w
Beukenhorst AL, Druce KL, De Cock D. Smartphones for musculoskeletal research - hype or hope? lessons from a decennium of mHealth studies. BMC Musculoskelet Disord. 2022 May 23;23(1):487. doi: 10.1186/s12891-022-05420-8
Primatesta P, Plana Hortoneda E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011 May 20;12:103. doi: 10.1186/1471-2474-12-103
Akashi-Ronquest N. The impact of biological preferences on parental investments in children and step-children. Rev Econ Househ. 2009 Mar 1;7(1):59-81.
Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.